Résumé
Objective To evaluate the efficacy and economy of electronic gastroscope and rigid endoscope on removal of esophageal incarceration foreign bodies. Methods Data of 60 patients with incarceration esophageal foreign body who underwent endoscopic removal of foreign bodies from June 2013 to June 2017 were retrospectively analyzed. They were divided into study group (n = 30) and control group (n = 30) based on the therapy way. The study group was given electronic gastroscope, and the control group was given rigid endoscope. Anesthesia method, success rate of therapy, incidence of endoscopy complication, hospitalization time and average cost of hospitalization were recorded. Results 13patients of study group received local anaesthesia, and 17 patients received intravenous anesthesia, all patients of control group received endotracheal intubation anesthesia. Success rate of therapy between the two group showed no significant difference (96.67% vs 100.00%, P > 0.05). There was no significant difference of the incidence of endoscopy complication between the two group (0.00% vs 3.33%, P > 0.05). Hospitalization time showed no significant difference between the two group [(1.70 ± 1.39) vs (2.20 ± 1.10) d, P > 0.05]. The average cost of hospitalization in study group was (2 022.00 ± 1 787.45) Yuan RMB, which was significantly lower than that of control group (5 078.00 ± 930.57, P < 0.05). Conclusion Both the way of electronic gastroscope and rigid endoscope are safe and efficient in removal of esophageal foreign bodies, but the former has more advantages in simplicity and economical efficiency.
Résumé
<p><b>OBJECTIVE</b>To summarize the experiences in gallbladder cancer treatment, evaluate the efficacy of postoperative radiotherapy, and investigate the method of improving the survival of gallbladder cancer patients.</p><p><b>METHODS</b>One hundred and twenty-seven gallbladder cancer patients, treated in our center by radical resection (84 cases) and combined with postoperative radiotherapy (43 cases), between June 2003 to December 2009 were included in this study. Their clinical data and follow-up results were retrospectively analyzed. According to AJCC staging criteria, the survival time and 1-, 3- and 5-year survival rates of the surgery group and the postoperative radiotherapy group at the different pathological stages and resection margin status were compared.</p><p><b>RESULTS</b>The median survival time of postoperative radiotherapy patients in stage III was 16.9 months, and the 1-year, 3-year, and 5-year survival rates were 55.7%, 23.5% and 18.2%, respectively, significantly higher than that of the simple operation group ( median survival time 14.3 months, and 1-year, 3-year, 5-year survival rates 42.7%, 22.6% and 16.7%, respectively) (P<0.05). The median survival time of postoperative radiotherapy patients in stage IV, the median survival time was 9.7 months in the postoperative radiotherapy group and 6.3 months in the simple surgery group, and the 1-year survival rates were 14.2% and 9.8%, the 3-year survival rates were 7.2% and 3.9%, the 5-year survival rates were 7.2% and 1.9%, respectively, all showing a statistically significant difference (P<0.05). Among the stage III and IVpatients, all the 1-, 3- and 5-year survival rates of the postoperative radiotherapy group were higher than that of the simple R0 and R1 surgical resection group (all P<0.05), but with a non-significant difference between the stageIandIIpatients (P>0.05). The main side effects in postoperative radiotherapy patients including nausea, vomiting and abdominal pain, all were successfully alleviated by symptomatic and supportive therapy, and the radiotherapy was successfully completed.</p><p><b>CONCLUSIONS</b>With regard to the gallbladder cancer patients in stage III and IV, the survival rate can be obviously increased by postoperative radiotherapy. However, for patients in stageIand II, whether postoperative radiotherapy significantly improves the survival or not, needs to be further validated in larger scale studies.</p>
Sujets)
Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Cholécystectomie , Méthodes , Études de suivi , Tumeurs de la vésicule biliaire , Radiothérapie , Chirurgie générale , Nausée , Stadification tumorale , Radiothérapie adjuvante , Radiothérapie conformationnelle , Études rétrospectives , Taux de survie , VomissementRésumé
<p><b>OBJECTIVE</b>To observe the effects of Huganjiexian decoction on rat hepatic fibrosis and the creation of cytokines.</p><p><b>METHODS</b>Rat hepatic fibrosis was induced by intraperitoneally injection of carbon tetrachloride. At the same time, these rats were treated with different dosages of Huganjiexian decoction. Sho-saiko-to compound treating group and Fufangbiejiarangan Tablets treating group were used as positive controls. After twelve weeks, all rats were executed. Histopathologic changes were observed after H.E and Masson stainings. The expression of collagen type I, collagen type III, TGF-beta 1 and PDGF-BB in liver were detected by immunohistochemical staining.</p><p><b>RESULTS</b>Compared with fibrotic group, hepatic fibrosis in decoction groups was significantly improved. In decoction groups, levels of collagen type I, collagen type III, TGFbeta1 and PDGF-BB were decreased, especially in the low-dose curcumin group. The TGF-beta 1 positive percentage were 7.56%+/-2.18%, 29.25%+/-7.84%, 13.54%+/-4.15%, 21.82%+/-6.64%, 20.06%+/-7.14%, 13.78%+/-4.35%, 12.75%+/-3.98% in liver tissues from normal group, model group, low, middle, high curcumin, Sho-saiko-to compound and Fufangbiejiarangan Tablets treating groups respectively (P less than 0.05); while the PDGF-BB positive percentage were 1.68%+/-0.41%, 11.70%+/-2.28%, 3.65%+/-0.76%, 5.24%+/-1.04%, 6.37%+/-1.12%, 4.16%+/-0.61%, 3.38%+/-0.56% in liver tissues from those groups respectively (P less than 0.05).</p><p><b>CONCLUSION</b>Huganjiexian decoction can improve rat hepatic fibrosis, possibly via inhibiting the expression of collagen type I, collagen type III, TGFbeta1 and PDGF-BB.</p>
Sujets)
Animaux , Mâle , Rats , Collagène de type I , Métabolisme , Collagène de type III , Métabolisme , Médicaments issus de plantes chinoises , Pharmacologie , Cirrhose du foie , Traitement médicamenteux , Métabolisme , Médecine traditionnelle chinoise , Phytothérapie , Facteur de croissance dérivé des plaquettes , Métabolisme , Protéines proto-oncogènes c-sis , Rat Sprague-Dawley , Facteur de croissance transformant bêta-1 , MétabolismeRésumé
0.05) in incidence rate for bone marrow suppression,gastrointestinal reaction,hepatic damage and mucosa damage and infection between different therapic courses.Central nervous system leukemia(CNSL) occured in one high risk case followed up at 12 month after complete remission(CR);the incidence rate was 12.5%.Conclusions HD-MTX is practicable in basic-level hospitals,as long as there are perfect preparation,fitness hydration and alkalization and leucovorin rescue being used in time.